Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) association with lymph node metastasis predicts poor survival in oral squamous cell carcinoma patients.
Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) association with lymph node metastasis predicts poor survival in oral squamous cell carcinoma patients.
复制标题
DOI：
10.18632/oncotarget.7681
复制
发表时间：
2016-03-08
期刊：
影响因子：
--
通讯作者：
Ko YC
中科院分区：
文献类型：
--
作者：
Velmurugan BK;Yeh KT;Lee CH;Lin SH;Chin MC;Chiang SL;Wang ZH;Hua CH;Tsai MH;Chang JG;Ko YC
富含亮氨酸的酸性核磷蛋白-32A(ANP32A)是一种多功能蛋白，在多种肿瘤中异常表达。然而，其在口腔鳞状细胞癌(OSCC)中的表达模式及其临床意义尚不清楚。本研究采用免疫组织化学Allred、Klein和免疫反应评分(IRS)法检测了259例口腔鳞癌组织中ANP32A的表达情况，并与临床病理因素进行了相关性分析。结果表明，ANP32A的高表达与口腔鳞癌患者的N分期和肿瘤分化程度显著相关。N0/N1期口腔鳞癌患者ANP32A高表达与N0/N1期患者相比，ANP32A高表达患者死亡风险增加。功能研究表明，ANP32A基因敲除可显著降低细胞的迁移和侵袭能力，从而增加E-钙粘蛋白的表达，降低slug、Claudin-1和Vimentin的表达。提示ANP32A在口腔鳞状细胞癌中普遍升高，ANP32A蛋白可作为评估口腔癌淋巴结转移患者预后的潜在生物标志物。
Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) is a multifunctional protein aberrantly expressed in various types of cancers. However, its expression pattern and clinical significance in oral squamous cell carcinoma (OSCC) remains unclear. In this study, we immunohistochemically investigated the expression pattern of ANP32A in 259 OSCC patients and the results were correlated with clinicopathological factors using Allred, Klein and Immunoreactive scoring (IRS) system. Our data indicated that high expression of ANP32A was significantly associated with N stage and tumor differentiation status in OSCC patients. High ANP32A expression with N2/N3 stage had an increased mortality risk than low ANP32A expressing OSCC patients with N0/N1 stage. Functional studies revealed that knockdown of ANP32A significantly decreased the migration and invasion ability thereby concomitantly increasing E-cadherin and decreasing Slug, Claudin-1 and Vimentin expression in vitro. These results suggest that ANP32A is commonly increased in oral squamous cell carcinoma and ANP32A protein could act as a potential biomarker for prognosis assessment of oral cancer patients with lymph node metastasis.